Allucent is a full-service CRO company focusing on the implementation of clinical oncology studies in Europe, with special expertise in early phase and immuno-oncology studies.
WntResearch has entered into an agreement with Allucent as a contract research company (CRO) for the implementation of the Phase 2 study with Foxy-5 – a drug candidate to counteract tumour spread. The company, with its head office in the Netherlands, is focused on conducting only clinical cancer studies and has a long-term establishment in Spain, as well as a solid experience of carrying out studies in these two countries. Allucent is a full-service CRO company focusing on the implementation of clinical oncology studies in Europe, with special expertise in early phase and immuno-oncology studies.